DOV-216,303
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C11H11Cl2N |
| Molar mass | 228.12g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?)(verify) | |
DOV 216,303is an experimentalantidepressantdrugoriginally developed byDOV Pharmaceuticaland was licensed toMerck & Co.in 2004;[1]Merck and DOV terminated their relationship in December 2006.[2]: 12 [3]
It is atriple reuptake inhibitor(TRI), orserotonin-norepinephrine-dopamine reuptake inhibitor(SNDRI).[4]It is theracemicmixture ofamitifadine(DOV-21,947) and its (–)-enantiomer,DOV-102,677.ItsIC50values forSERT,NET,andDATare Ki14 nM, 20 nM, and 78 nM, respectively.[4]
As of March 2008, DOV had no intention to further develop DOV-216,303 because the patent on the compound had expired.[2]: 6
In amouse model,DOV-216,303 has shown the ability to promote recovery after spinal cordcontusion.[5]
See also
[edit]References
[edit]- ^McCoy M (August 12, 2004)."Merck and DOV Pharmaceutical In Drug Pact".Chemical & Engineering News.
- ^ab"10-K For the fiscal year ended December 31, 2007".Dov Pharmaceutical via SEC Edgar. March 31, 2008.
DOV 216,303 was originally in development for depression; however as the patented composition of matter claim has expired, there are no ongoing clinical trials of DOV 216,303 and none are planned.
- ^"DOV 216303".Adis Insight.Springer Nature Switzerland AG.Retrieved26 February2017.
- ^abSkolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A (2006)."Preclinical and clinical pharmacology of DOV 216,303, a" triple "reuptake inhibitor".CNS Drug Reviews.12(2): 123–34.doi:10.1111/j.1527-3458.2006.00123.x.PMC6494125.PMID16958986.
- ^Chu TH, Cummins K, Stys PK (May 2018). "The triple monoamine re-uptake inhibitor DOV 216,303 promotes functional recovery after spinal cord contusion injury in mice".Neuroscience Letters.675:1–6.doi:10.1016/j.neulet.2018.03.050.PMID29578004.S2CID5007186.